Drug intelligence / Profile preview

HT24

Development stage: Preclinical
Lead developer: Suzhou Pharmavan Cancer Research Center
Modality: Small Molecules

Overview

HT24 is an investigational drug candidate currently in the preclinical stage of development by Suzhou Pharmavan Cancer Research Center. It is being developed for the treatment of inflammatory disorders. As a proprietary asset within the developer's pipeline, specific information regarding its biological target, mechanism of action, and pharmacological profile has not yet been publicly released. Suzhou Pharmavan focuses on the discovery of innovative small molecule drugs, suggesting HT24 is likely a small molecule inhibitor or modulator designed to address unmet needs in the immunology and inflammation space.

Beyond the preview

Go deeper on HT24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT24.

Explore the full profile